Asia
GC Biopharma to Invest 140 Billion Won in New Production Line at Ochang Plant in Korea
GC Biopharma (KRX:006280) said it approved a 140 billion won investment in a new production line at its Ochang manufacturing facility in Korea, according to a Thursday filing with the Korean bourse.The South Korea-based biopharma company said that the investment represents 10% of its equity capital ratio based on its end-2025 consolidated financial statements.The construction of the new facility will begin immediately, with completion expected by the end of 2030, and will help expand its next-generation immunoglobulin product offerings.
KRX:006280
